生物技术公司Vir Biotechnology(VIR)在夜盘交易时段股价大跌5.06%，引起了市场的关注。
消息面上，股价下跌的主要原因是该公司在常规交易时段股价大幅飙升后，于盘后宣布了发行2亿美元股票的计划。此类增发融资行为通常会稀释现有股东的权益，因此被市场视为短期利空消息，导致股价承压下行。
值得注意的是，在宣布增发前，Vir Biotechnology的股价在日间交易中曾因亮眼的第四季度业绩以及与安斯泰来制药（Astellas）达成的前列腺癌药物合作而大幅上涨。此次夜盘下跌可视为在利好兑现后，市场对公司融资行为的正常反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.